Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.44 |
| ▸ | DRD3 | P35462 | 9/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099111 | 0.91 | USP2 (0.41) | USP2MAPTGALR3HTR1AALDH1A1 | |
| SCHEMBL13099104 | 0.85 | DRD2 (0.42) | DRD2DRD3USP2MAPTALDH1A1 | |
| SCHEMBL13099083 | 0.84 | MAPT (0.38) | USP2MAPTALDH1A1JAK3 | |
| SCHEMBL13098780 | 0.83 | MAPT (0.41) | USP2MAPTALDH1A1JAK3 | |
| SCHEMBL13099187 | 0.83 | DRD2 (0.39) | DRD2DRD3MAPTTSHRJAK3 | |
| SCHEMBL13099208 | 0.81 | MAPT (0.42) | USP2MAPT | |
| SCHEMBL13098869 | 0.80 | MAPT (0.37) | USP2MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL9408126 | 0.80 | MAPT (0.41) | USP2MAPT | |
| SCHEMBL3101680 | 0.80 | MAPT (0.43) | USP2MAPTGALR3ALDH1A1TSHR | |
| SCHEMBL9407986 | 0.80 | GPR119 (0.47) | MAPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | DRD2 2677/4885DRD3 2427/4885USP2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.